Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.
Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
Evotec's Partner Zhejiang Jingxin Pharmaceutical Secures Approval From Chinese Medical Authority For Evotec's Insomnia Drug, EVT201
“Ate” 19 hospitals in one go, and Aier Ophthalmology went to the county
Aier Ophthalmology is already a “veteran” of industrial fund mergers and acquisitions. On September 21, Aier Ophthalmology announced that it plans to spend 860 million yuan to acquire some shares in a total of 19 ophthalmology hospitals, including Hainan Air and Zaozhuang Aier, held by 6 industrial investment funds. According to statistics from TradeWind01 (ID: TradeWind01), the total revenue of these 19 hospitals in 2022 and January to July 2023 could reach 523 million yuan and 379 million yuan respectively. Judging from the geographical location of the merger and acquisition targets, a total of 6 ophthalmology hospitals including Hanchuan Aier are located in county-level cities, and a total of 3 ophthalmology hospitals including Yuanling Aier